Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O60331

UPID:
PI51C_HUMAN

ALTERNATIVE NAMES:
Type I phosphatidylinositol 4-phosphate 5-kinase gamma

ALTERNATIVE UPACC:
O60331; B7Z9E7; C6GIJ7; C6GIJ8; Q7LE07

BACKGROUND:
Type I phosphatidylinositol 4-phosphate 5-kinase gamma plays a key role in phospholipid signaling, generating PtdIns(4,5)P2, a lipid second messenger vital for cellular functions including signal transduction and cytoskeleton dynamics. It is essential for synaptic vesicle endocytosis/exocytosis, clathrin-mediated endocytosis, and cell junction assembly. The protein's involvement in actin remodeling and focal adhesion points to its critical role in cell motility and adhesion.

THERAPEUTIC SIGNIFICANCE:
Given its association with Lethal congenital contracture syndrome 3, revealing the intricacies of Type I phosphatidylinositol 4-phosphate 5-kinase gamma's function offers promising therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.